Tara Ledford
Nurse Practitioner · Chattanooga, TNNPI 1265915383
Payments from drug & device makers
Across 140 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$445
- AbbVie$413
- Amgen$352
- AstraZeneca$233
- Pfizer$204
- Collegium Pharmaceutical, Inc.$189
- plus $989 from 16 others
What the payments were for
- Food & beverage$2,77098%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 22 | $445 |
| AbbVie | 16 | $413 |
| Amgen(2 entities) | 24 | $352 |
| AstraZeneca(2 entities) | 10 | $233 |
| Pfizer | 9 | $204 |
| Collegium Pharmaceutical, Inc. | 14 | $189 |
| Johnson & Johnson | 7 | $179 |
| Novartis | 6 | $123 |
| GSK | 5 | $105 |
| Sandoz | 5 | $104 |
| Mallinckrodt Hospital Products Inc. | 2 | $65 |
| Genentech USA, Inc. | 2 | $60 |
| Scilex Pharmaceuticals Inc. | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $55 |
| Boston Scientific | 1 | $50 |
| Fresenius Kabi USA, LLC | 2 | $32 |
| Radius Health, Inc. | 1 | $30 |
| Organon | 1 | $22 |
| GRT US Holding, Inc. | 1 | $18 |
| Biodelivery Sciences International, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $13 |
How this compares
$2,825 in reported general payments places this provider in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 947 | $27,629 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 599 | $15,836 |
| BelbucaBuprenorphine Hcl | 18 | $10,648 |
| MovantikNaloxegol Oxalate | 26 | $10,286 |
| Xtampza ErOxycodone Myristate | 27 | $10,234 |
| ZtlidoLidocaine | 13 | $9,378 |
| Naloxone Hcl | 145 | $9,058 |
| Oxycodone Hcl | 322 | $7,515 |
| Diclofenac Sodium | 266 | $7,171 |
| Lidocaine | 71 | $7,072 |
| OxycontinOxycodone Hcl | 12 | $6,756 |
| Fentanyl | 28 | $5,540 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 37 | $3,746 |
| Gabapentin | 332 | $3,424 |
| Buprenorphine | 25 | $2,957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $189 | $20,88145 claims |
| Redhill Biopharma Inc.Movantik | $13 | $10,28626 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $60 | $9,37813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Chattanooga
- Cynthia WilsonChattanooga$62K
- Honor HightshueChattanooga$45K
- Amy OttmanChattanooga$32K
- Philip AndrewsChattanooga$18K
- Amberly EllisChattanooga$17K
- Erin StockwellChattanooga$15K
- Teresa DeeseChattanooga$13K
- Jay PassmoreChattanooga$13K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.